MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Genes involved in the carcinogenetic mechanisms underlying malignant pleural mesothelioma (MPM) are still poorly characterized. So far, mesothelin (MSLN) has aroused the most interest. It encodes for a membrane glycoprotein, frequently over-expressed in various malignancies such as MPM, and ovarian...

Full description

Saved in:
Bibliographic Details
Main Authors: Ombretta Melaiu, Justin Stebbing, Ylenia Lombardo, Elisa Bracci, Norihisa Uehara, Alessandra Bonotti, Alfonso Cristaudo, Rudy Foddis, Luciano Mutti, Roberto Barale, Federica Gemignani, Georgios Giamas, Stefano Landi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0085935
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849722141893722112
author Ombretta Melaiu
Justin Stebbing
Ylenia Lombardo
Elisa Bracci
Norihisa Uehara
Alessandra Bonotti
Alfonso Cristaudo
Rudy Foddis
Luciano Mutti
Roberto Barale
Federica Gemignani
Georgios Giamas
Stefano Landi
author_facet Ombretta Melaiu
Justin Stebbing
Ylenia Lombardo
Elisa Bracci
Norihisa Uehara
Alessandra Bonotti
Alfonso Cristaudo
Rudy Foddis
Luciano Mutti
Roberto Barale
Federica Gemignani
Georgios Giamas
Stefano Landi
author_sort Ombretta Melaiu
collection DOAJ
description Genes involved in the carcinogenetic mechanisms underlying malignant pleural mesothelioma (MPM) are still poorly characterized. So far, mesothelin (MSLN) has aroused the most interest. It encodes for a membrane glycoprotein, frequently over-expressed in various malignancies such as MPM, and ovarian and pancreatic cancers. It has been proposed as a diagnostic and immunotherapeutic target with promising results. However, an alternative therapeutic approach seems to rise, whereby synthetic molecules, such as antisense oligonucleotides, could be used to inhibit MSLN activity. To date, such a gene-level inhibition has been attempted in two studies only, both on pancreatic and ovarian carcinoma cell lines, with the use of silencing RNA approaches. With regard to MPM, only one cell line (H2373) has been employed to study the effects of MSLN depletion. Indeed, the knowledge on the role of MSLN in MPM needs expanding. Accordingly, we investigated the expression of MSLN in a panel of three MPM cell lines, i.e., NCI-H28, Mero-14, and IstMes2; one non-MPM cell line was used as reference (Met5A). MSLN knock-down experiments on MSLN-overexpressing cells were also performed through silencing RNA (siRNA) to verify whether previous findings could be generalized to a different set of cell cultures. In agreement with previous studies, transient MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. Moreover, MSLN-siRNA combined with cisplatin, triggered a marked increase in apoptosis and a decrease in proliferation as compared to cells treated with each agent alone, thereby suggesting a sensitizing effect of siRNA towards cisplatin. In summary, our findings confirm that MSLN should be considered a key molecular target for novel gene-based targeted therapies of cancer.
format Article
id doaj-art-9a7e233c34fe48c28792f10342cc3e49
institution DOAJ
issn 1932-6203
language English
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-9a7e233c34fe48c28792f10342cc3e492025-08-20T03:11:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8593510.1371/journal.pone.0085935MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.Ombretta MelaiuJustin StebbingYlenia LombardoElisa BracciNorihisa UeharaAlessandra BonottiAlfonso CristaudoRudy FoddisLuciano MuttiRoberto BaraleFederica GemignaniGeorgios GiamasStefano LandiGenes involved in the carcinogenetic mechanisms underlying malignant pleural mesothelioma (MPM) are still poorly characterized. So far, mesothelin (MSLN) has aroused the most interest. It encodes for a membrane glycoprotein, frequently over-expressed in various malignancies such as MPM, and ovarian and pancreatic cancers. It has been proposed as a diagnostic and immunotherapeutic target with promising results. However, an alternative therapeutic approach seems to rise, whereby synthetic molecules, such as antisense oligonucleotides, could be used to inhibit MSLN activity. To date, such a gene-level inhibition has been attempted in two studies only, both on pancreatic and ovarian carcinoma cell lines, with the use of silencing RNA approaches. With regard to MPM, only one cell line (H2373) has been employed to study the effects of MSLN depletion. Indeed, the knowledge on the role of MSLN in MPM needs expanding. Accordingly, we investigated the expression of MSLN in a panel of three MPM cell lines, i.e., NCI-H28, Mero-14, and IstMes2; one non-MPM cell line was used as reference (Met5A). MSLN knock-down experiments on MSLN-overexpressing cells were also performed through silencing RNA (siRNA) to verify whether previous findings could be generalized to a different set of cell cultures. In agreement with previous studies, transient MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. Moreover, MSLN-siRNA combined with cisplatin, triggered a marked increase in apoptosis and a decrease in proliferation as compared to cells treated with each agent alone, thereby suggesting a sensitizing effect of siRNA towards cisplatin. In summary, our findings confirm that MSLN should be considered a key molecular target for novel gene-based targeted therapies of cancer.https://doi.org/10.1371/journal.pone.0085935
spellingShingle Ombretta Melaiu
Justin Stebbing
Ylenia Lombardo
Elisa Bracci
Norihisa Uehara
Alessandra Bonotti
Alfonso Cristaudo
Rudy Foddis
Luciano Mutti
Roberto Barale
Federica Gemignani
Georgios Giamas
Stefano Landi
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
PLoS ONE
title MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
title_full MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
title_fullStr MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
title_full_unstemmed MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
title_short MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
title_sort msln gene silencing has an anti malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
url https://doi.org/10.1371/journal.pone.0085935
work_keys_str_mv AT ombrettamelaiu mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT justinstebbing mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT ylenialombardo mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT elisabracci mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT norihisauehara mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT alessandrabonotti mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT alfonsocristaudo mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT rudyfoddis mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT lucianomutti mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT robertobarale mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT federicagemignani mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT georgiosgiamas mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma
AT stefanolandi mslngenesilencinghasanantimalignanteffectoncelllinesoverexpressingmesothelinderivingfrommalignantpleuralmesothelioma